AstraZeneca's MedImmune to appeal UK patent ruling
This article was originally published in Scrip
Executive Summary
MedImmune said it will seek permission to appeal a UK high court decision that went in favour of Novartis relating to an intellectual property dispute involving the vision loss medication, Lucentis (ranibizumab).